计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| P413284-5mg |
5mg |
现货 ![]() |
| |
| P413284-10mg |
10mg |
现货 ![]() |
| |
| P413284-25mg |
25mg |
现货 ![]() |
| |
| P413284-50mg |
50mg |
期货 ![]() |
| |
| P413284-100mg |
100mg |
期货 ![]() |
|
| 别名 | 帕瑞瑞韦 (ABT-450) |
|---|---|
| 英文别名 | (2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-6-(5-methylpyrazin-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16atetradecahydrocyclopropa(E)pyrrolo(1,2-a)(1,4)diazacyclopentadecine-14a(5H)-carboxamide | Cyclopr |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Paritaprevir (ABT-450) |
| 生化机理 | Paritaprevir (ABT-450)是一种非结构(NS)蛋白 3/4A 蛋白酶抑制剂。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 丙型肝炎病毒丝氨酸蛋白酶、NS3/NS4A 抑制剂 |
| 产品介绍 |
Information Paritaprevir (ABT-450) Paritaprevir (ABT-450) is a nonstructural (NS) protein 3/4A protease inhibitor. Targets HCV genotype 1b (in replicon cell culture assays); HCV genotype 1a (in replicon cell culture assays) 0.21 nM(EC50); 1 nM(EC50) In vitro Paritaprevir inhibits p-glycoprotein (p-gp) in vitro. ABT-450 is an efficacious inhibitor of HCV NS3/4A protease, with 50% effective concentration values of 1.0, 0.21, 5.3, 19, 0.09, and 0.69 nM against stable HCV replicons with NS3 protease from genotypes 1a, 1b, 2a, 3a, 4a, and 6a, respectively. The CC50 of ABT-450 is more than 37 μM, resulting in an in vitro selectivity index of ≥37,000-fold. ABT-450 demonstrates activity across multiple HCV genotypes, with an EC50 of 5.3 nM against the genotype 2a JFH-1 subgenomic replicon. In vivo After oral administration, paritaprevir reaches maximum concentrations in a mean of 4-5 h with increases in exposure more than dose proportional. Absolute bioavailability is about 50% after administering with food. It displays high (about 97-99.9 %) plasma protein binding and has apparent volumes of distribution of 16.7L. Paritaprevir metabolism occurs via CYP3A4 (predominantly) and CYP3A5. |
| 纯度 | ≥98% |
| ALogP | 4.7 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504770556 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | (1S,4R,6S,7Z,14S,18R)-N-cyclopropylsulfonyl-14-[(5-methylpyrazine-2-carbonyl)amino]-2,15-dioxo-18-phenanthridin-6-yloxy-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-ene-4-carboxamide |
| INCHI | 1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1 |
| InChi Key | UAUIUKWPKRJZJV-QPLHLKROSA-N |
| Smiles | CC1=CN=C(C=N1)C(=O)NC2CCCCCC=CC3CC3(NC(=O)C4CC(CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8 |
| Isomeric SMILES | CC1=CN=C(C=N1)C(=O)N[C@H]2CCCCC/C=C\[C@@H]3C[C@]3(NC(=O)[C@@H]4C[C@H](CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8 |
| PubChem CID | 45110509 |
| 分子量 | 765.88 |
| 溶解性 | Solubility (25°C) In vitro DMSO: 100 mg/mL (130.56 mM); |
|---|---|
| 分子量 | 765.900 g/mol |
| XLogP3 | 4.700 |
| 氢键供体数Hydrogen Bond Donor Count | 3 |
| 氢键受体数Hydrogen Bond Acceptor Count | 10 |
| 可旋转键计数Rotatable Bond Count | 7 |
| 精确质量Exact Mass | 765.294 Da |
| 单同位素质量Monoisotopic Mass | 765.294 Da |
| 拓扑极表面积Topological Polar Surface Area | 198.000 Ų |
| 重原子数Heavy Atom Count | 55 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 1600.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 5 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 1 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 1 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS07 |
|---|---|
| 信号词 | 警告 |
| 危险声明 |
H302: 吞食有害 H315: 引起皮肤刺激 H319: 引起严重眼睛刺激 H335: 可能引起呼吸道刺激 |
| 预防措施声明 |
P261: 避免吸入灰尘/烟雾/气体/雾/蒸汽/喷雾 P305+P351+P338: 如进入眼睛:用水小心冲洗几分钟。如戴隐形眼镜并可方便地取出,取出隐形眼镜。继续冲洗。 |
| 1. Carrion AF, Gutierrez J, Martin P. (2014) New antiviral agents for the treatment of hepatitis C: ABT-450.. Expert Opin Pharmacother, 15 (5): (711-6). [PMID:24517400] |